ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » California » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in California

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
GARY REZNIK MD

Cardiovascular Disease

46,107

$4.67M

1260
1234 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 28%

$101
Average prescription price

Avg: $67

JOSE ROCAMORA MD

Cardiovascular Disease

45,055

$2.14M

1473
1174 are 65+

1%
patients receiving schedule two controlled substances

Avg: 0%

21%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 28%

$48
Average prescription price

Avg: $67

RAZMIK OHANJANIAN MD

Cardiovascular Disease

43,890

$3.05M

723
667 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

20%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 28%

$69
Average prescription price

Avg: $67

HENRY YEE MD

Cardiovascular Disease

37,321

$3.8M

1370
1278 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 28%

$102
Average prescription price

Avg: $67

TOM YEH M.D.

Cardiovascular Disease

28,209

$1.52M

772
749 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$54
Average prescription price

Avg: $67

AFSHINE EMRANI MD

Cardiovascular Disease

25,794

$3.1M

629
555 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

63%
prescriptions for brand name drugs

Avg: 28%

$120
Average prescription price

Avg: $67

NGAI NGUYEN MD

Cardiovascular Disease

25,657

$3.37M

1277
1207 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

49%
prescriptions for brand name drugs

Avg: 28%

$131
Average prescription price

Avg: $67

ANNA MILSTEIN M.D.

Cardiovascular Disease

23,986

$2.21M

664
618 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

52%
prescriptions for brand name drugs

Avg: 28%

$92
Average prescription price

Avg: $67

OSCAR ZAMBRANO M.D.

Cardiovascular Disease

22,733

$918K

1008
870 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

12%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 28%

$40
Average prescription price

Avg: $67

MICHAEL NORMAN DO

Cardiovascular Disease

21,812

$1.15M

1157
938 are 65+

6%
patients receiving schedule two controlled substances

Avg: 0%

20%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 28%

$53
Average prescription price

Avg: $67

GUSTIN HO M.D.

Cardiovascular Disease

21,804

$1.49M

1208
1174 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 28%

$68
Average prescription price

Avg: $67

TAO DUONG M.D.

Cardiovascular Disease

21,731

$1.67M

1063
997 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

45%
prescriptions for brand name drugs

Avg: 28%

$77
Average prescription price

Avg: $67

PRAMOD MULTANI MD

Cardiovascular Disease

21,714

$1.21M

781
673 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

16%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$56
Average prescription price

Avg: $67

MINH NGUYEN MD

Cardiovascular Disease

20,502

$1.26M

706
598 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 28%

$61
Average prescription price

Avg: $67

CHIN SHUN SHIH M.D.

Cardiovascular Disease

19,572

$1.19M

937
903 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 28%

$61
Average prescription price

Avg: $67

JUAN ALMAGUER MD

Cardiovascular Disease

19,375

$1.11M

673
600 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 28%

$57
Average prescription price

Avg: $67

STEPHEN KWAN M.D.

Cardiovascular Disease

18,688

$1.43M

569
543 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 28%

$76
Average prescription price

Avg: $67

JENCHEN YANG M.D., PH.D

Cardiovascular Disease

18,487

$1.95M

916
887 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 28%

$105
Average prescription price

Avg: $67

JOHN TZENG M.D., PH.D.

Cardiovascular Disease

17,845

$1.07M

873
844 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

41%
prescriptions for brand name drugs

Avg: 28%

$60
Average prescription price

Avg: $67

RAMA THUMATI MD

Cardiovascular Disease

17,733

$453K

1253
1161 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 28%

$26
Average prescription price

Avg: $67

THAI NGUYEN M.D.

Cardiovascular Disease

16,878

$535K

638
575 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 28%

$32
Average prescription price

Avg: $67

JAMES LIU M.D.

Cardiovascular Disease

16,703

$2.07M

524
475 are 65+

4%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

58%
prescriptions for brand name drugs

Avg: 28%

$124
Average prescription price

Avg: $67

AARON JORDAN MD

Cardiovascular Disease

16,694

$704K

633
541 are 65+

7%
patients receiving schedule two controlled substances

Avg: 0%

27%
patients receiving schedule three controlled substances

Avg: 2%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 28%

$42
Average prescription price

Avg: $67

ALBERT SHARF MD

Cardiovascular Disease

16,547

$805K

807
683 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 28%

$49
Average prescription price

Avg: $67

GUSTAVO MONDRAGON M.D.

Cardiovascular Disease

15,979

$572K

596
514 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$36
Average prescription price

Avg: $67

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank